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Summary
CD2 subserves both adhesion and signal transduction functions in T cells, thymocytes, and natural
killer (NK) cells. In mature T lymphocytes, CD2-mediated signaling function apparently requires
surface expression of T cell receptors (TCRs). In contrast, in CD2+CD3- NK cells and
thymocytes, signal transduction through CD2 is TCR independent. To resolve this paradox and
characterize TCR-independent triggering mechanisms, we transfected a human CD2 cDNA into
a murine mast cell line, C1.MC/57 (Fcc-Rl+, FcyRII+, FcyRIII+), which is known to produce
interleukin 6 (IL6) as well as release histamine in response to crosslinking of FceRI. In the CD2
transfectant, a combination of anti T112 + antiT113 monoclonal antibodies (mAbs) induced a
rise in intracellular free calcium ([Ca2+]i), 11,6 production, and histamine release. As expected,
no activation was mediated by the same mAbs in C1.MC/57. F(ab)'2 fragments of the activatory
combination of antiT112 + antiT113 mAbs induced IL-6 in the CD2-transfected mast cells,
demonstrating an Fcy receptor ectodomain-independent triggering mechanism. In addition, either
intact anti-T112 or anti-T113 IgG alone, which failed to induce [Ca2+]i mobilization in the
transfectant, was able to induce IL6 production. A mAb directed against both FcyRII (previously
denoted as Fc-yRIIb) and FcyRIII (previously denoted as FcTRIIa) inhibits this induction.
These results indicate that: (a) Cat+ mobilization is not essential for IL6 production; and (b)
crosslinking of CD2 and Fcy receptors via intact anti-CD2 IgG stimulates 11,6 production. Thus,
CD2-mediated IL6 production occurs by both Fc receptor ectodomain-independent as well as
Fc receptor ectodomain-dependent mechanisms in these nonlymphoid cells. Northern blot analysis
demonstrates that although the mast cells do not express CD31' or CD3vl mRNA, they express
Fcc-RIy mRNA. The latter is a known component of FcyRIII as well as FceRI, has significant
homology to CD31'/t, and is thought to have a signal transduction function. In these mast
cells, CD2 signaling machinery does not require CD31'/rl and may be linked to the Fcc-RIy
subunit. We predict that this subunit or a related structure may confer a TCR-independent signal
transduction pathway upon CD2 in CD3- NK cells, thymocytes, and certain B lymphocytes.
T
he CD2 (T11 structure) has been shown to play an im-
portant role in the function of both thymus-derived T
cells and NK cells (1, 2). mAbs directed against an epitope
(T11i) within the NH2-terminal adhesion domain of CD2
block the ability of T cells (3-5), thymocytes (6), and NK
cells (4) to interact with the LFA-3-expressing cognate partners.
Predictably, therefore, helper and cytotoxic T cell responses,
thymocyte-epithelial conjugate formation, and lytic efFector
function of NK cells are reduced or eliminated by such mAbs.
Also, the adhesion function ofCD2 molecule has been shown
to directly contribute to the T cell recognition of nominal
antigen (7, 8). In addition to the adhesion function ofCD2,
mAbs directed at a second adhesion domain epitope (T112),
in concert with a mAb specific for an epitope (T113) within
the membrane proximal domain, activate T lymphocytes (3,
4), thymocytes (9), and NK cells (4). Moreover, the cellular
CD2 ligand LFA-3 itself, in conjunction with antiT113
mAb, can activate T cell responses (10). Collectively, these
findings indicate an important role for CD2, not only in func-
tioning as an adhesion structure, but also as an activation
receptor.
The signal transduction function of CD2 is dependent on
its CD2 cytoplasmic tail (11-13). Truncationanalysis and site-
directed mutagenesis have pinpointed a region between amino
acid residues 253 and 287 that is necessary for IL-2 gene in-
duction and increase in intracellular free calcium ([Ca 2+],)t
(11) . Disruption of a single histidine and arginine at posi-
tions 264 and 265 within the first of two tandem PPPGHR
repeat sequences can abrogate or dramatically reduce T cell
activation (14). The activation of T lineage cells via CD2
is also dependent on other cellular structures. In this respect,
studies conducted on a TCR - variant of the human T cell
1 Abbreviations used in this paper: [Ca 2'
l;, intracellular free calcium; PTK,
protein tyrosine kinase.
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cells could not be stimulated via CD2 (15). Reconstitution
of TCR surface expression in these Jurkat mutants by Tia
gene transfection restored CD2 triggering function. These
findings directly demonstrate that the CD2-mediated signal
transduction pathway is dependent on the expression of TCR
and that both TCR and CD2 activation pathways in T cells
are interconnected. Two indirect lines of evidence also sup-
port this notion in T lymphocytes. First, prior crosslinking
of TCR inhibits subsequent CD2-mediated activation (16-18).
Second, submitogenic concentrations of antiTCR mAbs and
anti-CD2 mAbs, which independently fail to activate T cells,
in combination induce T cell proliferation (19). The impor-
tance of TCR expression for CD2 signal transduction func-
tion has been further emphasized by the failure of CD2 to
trigger activation events when transfected and expressed in
SF9 (Spodopterafrugiperda) worm gut epithelial cells (20) or
murine fibroblasts (21) .
Despite the dependence ofCD2 function on surface TCR
expression in T lymphocytes, both thymocytes and NK cells
that lack surface TCR can be triggered upon CD2 stimu-
lation to increase [Ca2
+]i and mediate cytotoxic activity,
respectively (4, 9). The basis of this seemingly paradoxical
TCRindependent CD2 signal transduction function is un-
known, although we have speculated that it may result from
the coupling of CD2 to other transduction elements in NK
cells (1). A likely candidate that might functionally interact
with the CD2 pathway in these CD2 'CD3 - NK cells is
FcyRIII (CD16). CD16 has recently been shown to be phys-
ically associated with CD3f (22, 23) and is also thought to
associate with the y subunit of FceRI (FceRIy) (24). The
latter is a component of the tetrameric high affinity IgE
receptor expressed on mast cells and basophils (25), whose
broader tissue distribution is only now becoming apparent
(26). Interestingly, CD3(' and FceRI-y belong to the same
gene family located on murine chromosome 1 and are ho-
mologous at the primary sequence level(27, 28). Thus, TCR
independent CD2 signal transduction might be linked to ei-
ther C133f or Fcc-RIy or both.
To investigate these possibilities, we transfected a human
CD2 cDNA into murine mast cells that express FcERIy as
a component of their FceRI as well as FcyRIII (previously
denoted as FcyRIIa in mouse) and examined the ability of
CD2 to trigger [Ca 2+1, increase and IIr6 production. The
results demonstrate that CD2 is competent to transduce signals
in mast cells, henceproving that TCR expression and/or lym-
phoid phenotype is not required for CD2 function. Moreover,
because the mast cell line lacks both CD3fand CD3,q mRNA,
neither CD3(' nor CD3vl is required for CD2 signaling.
Materials and Methods
Cell Lines and Transfection of Human CD2.
￿
A ~o-2 helper-free
retrovirus packing cell line, which has been transfected with the
expressionvector DOL carrying both the neomycin resistance gene
and a cDNA of human CD2, was used to generate virus stocks
for the infection of mast cells (11). A growth factor-independent
mast cell line, C1.MC/57 (denoted as MC/57 in the text below),
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derived from C57BL/6J mouse bone marrow was a kind gift from
S. Galli(Beth IsraelHospital, Boston, MA) (29). MC/57 mast cells
were maintained in DME (Whittaker MA Bioproducts, Walkers-
ville, MD) supplemented with 10% heat-inactivated FCS (Sigma
Chemical Co., St. Louis, MO), 5 x 10 -s M 2-ME (Sigma Chem-
ical Co.), 2 MM L-glutamine, and 1% penicillin-streptomycin (Gibco
Laboratories, Grand Island, NY). Procedures for the growth of9-2
cells, harvesting of virus, and infection of MC/57 mast cells were
performed as described (11). The MC/57 mast cell line was infected
with freshly derived virus stocks in the presence of 8 ug/ml poly-
brene (Aldrich Chemical Co., Milwaukee, WI), and selection was
initiated 48 h later in 2 mg/ml of G418 (geneticin; GibcoLabora-
tories). The G418-resistant colonies were screened by indirect im-
munofluorescence as described below. Additional cell lines used in
this study, 2B4.11 and MA5.8, were provided byJ.D. Ashwell (NIH,
Bethesda, MD), and MH60.BSF2was a gift from T Hirano and
T. Kishimoto (Institutefor Molecular & Cellular Biology, Osaka
University, Osaka, Japan) (30).
Flow Cytometric Analysis.
￿
Phenotypic analyses were performed
using indirect immunofluorescence assays. 10' cells were analyzed
in each sample on an Epics V cell sorter, and results were expressed
as histograms displayingnumber ofcells vs. fluorescence intensity
on a log scale. A 1:400 dilution ofascites containing IgE anti-DNP
mAbs (31) (Hl-DNP-E-26, provided by S. Galli), a 1:200 dilution
of ascites containing either anti-T11, (3Pt2H9, IgGl) (3), anti-T112
(1old24C1, IgG2a) (3), or anti-T113 (lmono2A6, IgG3) (3) mAbs,
and culture supernatant containing monoclonal anti-H-2Db (AF6-
88.5.3, IgG2a, kindly provided by K. Rock, Dana-Farber Cancer
Institute) (32) were used in this study. Saturating amounts of an
anticlonotypic mAb, 11C5 (IgG1 derived in our lab; 1:200 dilution
of ascites), was used as a control to subtract background Fey receptor
binding. Cells incubated with the above mAbs for 30 min at 4°C
were washed with HBSS containing 2% FCS. The antibody bound
was detected with a 1:40 dilution of fluorescein-conjugated goat
anti-mouse IgG (H + L) second antibody (Whittaker MA Bio-
products) by using the Epics V cell sorter. CD2 transfectants were
sorted for higher levels ofCD2 expressionon the EpicsV cell sorter
by staining up to 5 x 106 cells as described above.
Determination ofCytosolic;free Ca2' by Indo-1 Fluorescence
￿
[Ca2'];
was determined according to Grynkiewicz et al. (33). Briefly,
2 x 106 cells were suspended in 200 pl of DMEM containing 10%
FCS and 2 F6g/ml acetoxymethylester of Indo-1 (Molecular Probes,
Junction City, OR) for 30 min at 37°C. Cells were then diluted
up to 1 ml with DME containing 10% FCS and kept at 37°C
before analysis on the EpicsV cell sorter. For determination of trig-
gering through FceRI, cells were incubated with a 1:400 dilution
of ascites containing IgE anti-DNP mAb for 30 min at room tem-
perature and washed twice as described above before loading with
Indo-1. The ratio of Indo-1 fluorescence at 410 nm to that at 480
nm was recorded in real time and expressed in arbitrary units, each
of which represents -200 nM [Ca2'];. Samples were analyzed at
room temperature by running the Indo-l-loaded cells on the Epics
V cell sorter for 1 min to establish a baseline before adding the
following stimuli: 100 ng/ml DNP-BSA (Sigma Chemical Co.),
a 1:100 dilution of antiT112 + antiT113, or a 1:100 dilution of
anti T112 + control mAb (antiT8, 1mono2E7, an IgG3 isotype-
matched mAb for anti-T113). Cells that did not show [Ca2+ );
mobilization received 1 hg/ml ofcalcium ionophore A23187 (Sigma
Chemical Co.). All concentrations indicated above are final con-
centrations of the respective stimuli.
11,6 Production Assays.
￿
Quantitation of 11,6 secreted into the
culture supernatant after stimulation of mast cells was analyzed
by bioassay. 106 mast cells were plated in 24-well plates and in-cubated at 37°C, 5% C02, for 24 h with the following panel of
stimuli: antiT112 + antiT113, antiT112 + control IgG3 (antiT8,
1mono2E7, a control irrelevant isotype-matched mAb for anti-
T113), antiT112, antiT113, control IgG2a (anti-T1, 24T6G12, a
control irrelevant isotype-matched mAb for anti-T112), control
IgG3, DNP-BSA, PMA, and media. All of the above-mentioned
antibodies were protein Apurified andincubatedat a finalconcen-
tration of 10 jig/ml. DNP-BSAandPMAwere used at a finalcon-
centration of 100 ng/ml. Mast cells that were triggered through
Fcc-RI were incubatedwith IgE anti-DNPmAb for30 min at room
temperature andwashed twice as described abovebefore stimula-
tion with DNP-BSA. For studies conducted on CD2 activation
after Fcy receptor blockade, amAb, 2AG2, that recognizes both
mouse FcyRII and FcyRIII (34) (kindly provided by J.-P. Kinet,
NIH) was used at 5 hg/ml either alone or in the presence of anti-
T112 mAb. In other experiments, antiT112 mAb stimulation was
tested in the presence of 10-100 Ftg/ml of control IgG2a isotype-
matched mAb. Supernatants harvested after 24 h were titrated in
triplicate in serial fivefold dilutionsfortheir ability to support the
growth ofan U,6-dependent murine hybridomacloneMH60.BSF2
(30). Simultaneously, triplicates of twofold serial dilutionsof rIL6
(a kind gift of Ajinomoto Co. Inc., Tokyo, Japan) were prepared.
MH60.BSF2cellscultured in RPMI containing 10% FCSand200
pg/mlrIL6 were washed andthen cultured for6hbefore theassay
in the absence of 11,6. Subsequently, 104 MH60.BSF2 cells were
added to each well of96-wellplates (fiat-bottomed) containing ei-
ther dilutions of samples or rIL6 andcultured for 44 h at 37°C,
5% C02, and pulsed with 1 pCi/well [3H]thymidine (ICN Bio-
medicals Inc., Irvine, CA) during thelast 7 h of incubation. The
cells were harvested on glass fiber filter papers and incorporation
of ['H]thymidine wasdetermined by a liquid scintillation counter.
Results are expressed as rIL6 equivalent (ng/ml/106 cells) produc-
tion as determined from the standard titration curve of rIL6 in
triplicate samples.
Generation of F(ab)'2 Fragments.
￿
F(ab)'2 fragments for anti-T112
and antiT113 mAbs were produced using the Immunopure F(ab)'2
preparation kitas recommendedby the manufacturer (Pierce Chem-
ical Co., Rockford, IL). 2mg of protein A-purified antiT11 mAbs
(6 mg/ml) that were dialyzed against 20 mM sodium acetate
buffer, pH 4.5 were incubatedwith 450pl ofthe appropriate diges-
tion buffer containing 150 p,l of immobilized pepsin in a shaker
water bath at 37°C. The anti-T112 (IgG2a) and anti-T113 (IgG3)
mAbs were digested for either 60 minin digestion buffer, pH 4.1,
or for 15 minin digestionbuffer,pH 4.3,respectively. Thedigested
F(ab)'2, Fc fragments andundigested IgG were recovered from im-
mobilizedpepsin and, subsequently, theFc fragmentsandundigested
IgG were depleted on a protein A column as outlined in the pro-
tocol for the kit. Briefly, each anti-T112 and anti-T113 crude digest
wasaddedto separate immobilized protein A columnsequilibrated
with bindingbuffer andincubatedfor 1 h. Thereafter, thecolumns
were washed with binding buffer and the flow through fractions
containing the F(ab)'2 fragments were collected and dialyzed
against PBS, pH 7.4, in dialysis tubing with a molecular weight
cut offof 50,000 to remove any small Fc fragments that did not
bind protein A. The purity of the protein A-purified F(ab)'2 frag-
mentswas checkedby nonreducing and reducing SDS-PAGE using
Coomassie G-250 staining and was >95%.
Histamine Release.
￿
Histaminereleaseinto culture supernatants
after stimulation of mast cells was analyzed using the histamine
radioimmunoassay kit (Amac Inc., Westbrook, ME). 106 mast cells
were stimulated for 10 and 60 min with either anti-T112 + anti-
T113, antiT112, or DNP-BSA. Mast cells triggered with DNP-
BSA were incubated with monoclonal IgE anti-DNP-BSA and
861
￿
Arulanandam et al.
washed as describedabove before stimulation. Histamine released
in culture supernatants afteractivation wasanalyzed accordingto
the manufacturer's recommendations. Briefly, 100 pl of samples
or histamine standards was added to acylation tubes containing
acylatiog agent. The acylated histamine was subsequently added
into tubes coated with mAb to acylated histaminein thepresence
of "1I-labeledacylated histamine. After incubation for 18 h at 4°C,
tubes were emptied and counted for 1 min in a gamma counter.
Results are expressed as nM histamine per 106 cells/ml by com-
parison oftheradioactivity boundto astandard curverunin parallel.
Northern Blot Analysis.
￿
TotalRNA wasisolated from cell lines
usingguanidineisothiocyanate (35). RNAconcentrations were mea-
sured spectrophotometrically and10,ug of totalRNA wasrunper
lane on a 1% agarose gelcontaining 2.2 M formaldehyde and 1x
MOPS buffer (35). The RNA was then transferred to nitrocellu-
lose in 20x SSC and theRNAblot hybridized to a CD3rt-specific
probe containing the3' AvaII/EcoRI fragment of pBS17 (36). Hy-
bridization was carried out in a solution containing 50% forma-
mide, 5x SSC, 5x Denhardt's, 250Ag/mldenaturedsalmon sperm
DNA, 50 mM NaHP04, pH 6.5, at 42°C for 16-20 h with 106
cpm/ml probe. Subsequently, theblotwaswashed in 2x SSC, 0.1%
SDS for 15-30 minat room temperature and0.1x SSC, 0.1% SDS
at 50°C for30 min, andwas exposedto KodakXOmat AR X-ray
film at -70°C for theindicated time. Theblot was then stripped
by boiling in distilled water for 10 min and exposed for 12-14 h
to insure that all signals had been removed. The filter was then
hybridized to the CD3~-specific probe containing the 3' EcoNI/
EcoRl fragment of pBS23 (37) using conditions as described for
theCD3rt-specific probe, washed,andautoradiographed. Afterstrip-
ping once again, theblot was hybridized to therat Fcc-RI-y-specific
cDNA probecontaining the3' BamHI/Xbal fragment (25) using
the same conditions described above.
Results
Generation of Human CD2-expressing Murine Mast Cell
Lines. To generate CD2 surface expression in mast cells,
MC/57 cellswere infected with the defectiveretrovirus vector
DOL, which bears the human CD2 cDNA and neomycin-
resistantgene (11), and subsequently, astable mast cell trans-
fectant was selected by flow cytometryas describedin Materials
andMethods. As shown in Fig. 1, whereastheparental mast
cell line, MC/57, does not show anydetectable levelofhuman
CD2 expression (Fig. 1 a), the human CD2 transfectant
C1.MC/57/64.1(denoted as MC/64.1 in thetext below) ex-
presses surface CD2 as judged by its reactivity with mAbs
to the distinct CD2 epitopes T11t, T112, and T113 (Fig. 1
df). Thelevelof CD2 expressedin thesecellsis comparable
with that of the endogenous H-2Db molecules (Fig. 1, c and
h) . Both the parental andCD2-transfected mast cell linesex-
press equivalent levels of Fcc-Rl (Fig. 1, b and g). These cells
also express equivalent levels of both FcyRII (previously
denoted as Fc-yRIIb) and FcyRIII (previously denoted as
Fc-yRIIa) (data not shown). Neither MC/57 nor MC/64.1
express TCR as judged by indirect immunofluorescence
staining with antimurine CD3e mAb, 145.2C11 (data not
shown).
Human CD2-mediated (Ca 2+J Changes in CD2-transferred
Mast Cells. Next, the ability of CD2 to trigger a rise in
[Ca2+]i in the MC/64.1 mast cell transfectant was examined.Untransfected
(C1 .MC/57)
CD2
Transfected
(ClAC/64.1)
b FcERI C
￿
H-2Db
Figure 1.
￿
Flow cytometry analysis of human CD2-transfected and
-untransfected mast cells. Human CD2-transfected MC/64.1 mast cells
treated with anti-T111 (d), anti-T112 (e), or anti-T113 (f) (bold lines). Un-
transfectedMC/57 mast cells treated with anti-T111 mAb (a) (bold line).
C132-transfected (g) and -untransfected (b) mast cells treated with IgE
anti-DNP mAb (bold lines). C132-transfected (h) and -untransfected (c) mast
cells treated with anti-H-21)b (bold lines) . C132-transfected and -untrans-
fected mast cells treated with a control 11C5 antibody (faint lines) . Anti-
body binding was detected by a fluorescein-conjugated goat anti-mouse
IgG antibody. The ordinate denotes cell number.
To this end, changes in [Ca2+] ; triggered through FceRI and
CD2 were assessed in Indo-l-loaded cells after specific anti-
body addition and subsequent receptor crosslinking . As shown
in Fig. 2, a and c, crosslinking of the FceRI with mono-
clonal IgE anti-DNP and DNP-BSA (anti-DNP-IgE/DNP-
BSA) resulted in a prompt increase in the level of [Ca2+] ;
in both the parental MC/57 and CD2-transfected MC/64.1
mast cell lines, consistent with FceRI-mediated activation of
Figure 2.
￿
Increase in [Ca2+ li after CD2 and FceRI triggering. Changes
in [Ca2+li were monitored in cells loaded with the Ca 2+-sensitive dye
Indo-1 . Cells were stimulated with either a combination of anti-T112 +
antiT113 or antiT112 + control (an isotype-matched IgG3 mAb for anti-
T113) (1), DNP-BSA (p), or calcium ionophore A23187 (") . Results are
expressed as ratio of Indo-1 fluorescence at 410 nm to that of 480 run
in arbitrary units (ordinate) vs. time in minutes (abscissa). One arbitrary
unit represents -200 nM [Ca2+li .
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Table 1 .
￿
IL-6 Induction in Mast Cells through Human CD2
or FceRI
Stimulus
IL-6 produced by :
Parental mast
￿
C132-transfected
cell line
￿
mast cell line
(C1.MC/57) (C1.MC/64.1)
Exp . I
￿
Exp . 1
￿
Exp . 2
ng/ml/10 6 cells
Media
￿
0.7 0.1 0.4
Anti-T112 +anti-T113 ￿1 .8
￿
2,300
￿
ND
Anti-T11 2+controlIgG3
￿
ND
￿
1,200
￿
ND
Anti-T11 2 ￿ND 1,500 2,700
Anti-T113 ￿ND 1,100 ND
Control IgG2a
￿
ND
￿
1.1
￿
ND
Control IgG3
￿
ND
￿
1.0
￿
ND
Anti-H-213b
￿
ND
￿
8
￿
ND
Anti-DNP-IgE/DNP-BSA 170 110 860
PMA
￿
2,400 2,100 2,100
The amount of IL-6 present in culture supernatants was assessed from
the titration of culture supernatants and rIL-6, as shown in Fig . 3, and
is expressed in rIL-6 equivalents . Control IgG2a is a control mAb iso-
type matched for anti-T112 . Control IgG3 is a control mAb isotype
matched for anti-T113. SD of IL-6 concentrations were <20% . Results
are representative of more than six experiments .
afunctional signal transduction machinery in both cell types
(38) . In contrast, as shown in Fig . 2, stimulation ofMC/64.1
cells (d) but notMC/57 cells (b) with anti T112 + anti T113
mAbs resulted in an increase in the level of [Ca 2+]i . The in-
crease in [Ca2+]i after addition of anti-T112 + anti-T113
mAbs is therefore attributable toCD2expression on MC/64.1
cells. Note that a nonmitogenic combination of antiT112 +
controlmAb (an irrelevant, IgG3 isotype equivalent to that
of antiT113 mAb) did not induce a measurable increase in
the level of [Ca2+] i in MC/64.1 cells (Fig . 2 e) . Neverthe-
less, the MC/64.1 cells were efficiently loaded with Indo-1
as judged by the ability of the calcium ionophore A23187
to increase [Ca 2+]i (Fig. 2 e, arrowhead) . These findings in-
dicate that both T112 and T113 epitopes on the MC/64.1
mast cells need to be ligated by antibody in order to increase
[Ca2+]i mediated throughCD2. Hence, these data are con-
sistent with earlier studies in T cells, thymocytes, and NK
cells, demonstrating that the addition of both anti T112 +
anti-T113 mAbs triggers a [Ca2
+]i flux (3-5, 9) .
Induction of11,6Production in CD2-turns .fectedMast Cells with
Anti-CD2 mAbs. Stimulation ofbone marrow-derived mast
cell lines including MC/57 through their FceRI was previ-
ously shown to result in induction of a number of cytokine
genes including 1176 (38) . To determine whether stimulation
ofCD2 would result in IL6 production from the MC/64.1
transfectant, culture supernatants from either the parental5
,
5 2 53 54 55 56
Reciprocal of Dilution
Figure 3.
￿
Titration ofIIr6 induced in mast cells through either human
CD2 or FceRI. Fivefold dilutions of culture supernatants from CD2-
transfected and -untransfected mast cells treated with the various stimuli
were titrated on the I1,6-dependent MpH60.BSF2 B cell clone as described
in Materials and Methods. The lines shown in the figure correspond to
the following cells and stimuli: MC/64.1 media (O), MC/64.1 anti-T112
+ anti-T113 ("), MC/57 media (A), MC/57 anti-T112 + anti-T113 (A),
MC/57 monoclonal anti-DNP IgE/DNP-BSA (0), and twofold dilutions
of 1 ng/ml ofrI1r6 (dotted line). 10% of the original culture supernatant
corresponds to the first dilution. The SD of [3H]thymidine incorporation
is indicated at each point. The ordinate represents [3H]thymidine incor-
poration (x 10 -4) .
MC/57 or MC/64.1 lines treated with various stimuli were
assayed for IL6 activity. For comparison, IL-6 production
stimulated via FceRI was examined in parallel. As expected,
the stimulation of both MC/57 and MC/64.1 lines through
their FceRI receptors with a combination of anti-DNP-IgE
and DNP-BSA resulted in production of IL6 (Table 1, Fig.
3). More importantly, the CD2-transfected MC/64.1 mast
cell line produced 11,6 when stimulated with a combination
of anti-T112 + antiT113 mAbs. In contrast, treatment of the
same cells with media or the parental MC/57 mast cells with
anti T112 + anti-T113 mAbs failed to induce IL-6 production
(Fig. 3, Table 1). In fact, the amount of IL-6 produced by
CD2 stimulation was greater than that after FceRI stimula-
tion in MC/64.1 cells by a factor of 20. Thus, signal-
ling through CD2 with antiT112 + antiT113 mAbs in
MC/64.1 mast cells results in both an increase in [Ca2+]i
and 11,6 production.
Somewhat unexpectedly, we observed that stimulation of
MC/64.1 mast cells with either antiT112 or anti T113 mAbs
alone also generated significant IL6 production. As shown
in Table 1, MC/64.1 mast cells stimulated with a combina-
tion of antiT112 + control IgG3 (an irrelevant mAb iso-
type matched to antiT113 mAb) produced a substantial
quantity of IL-6 relative to MC/64.1 cells stimulated with
media or parental MC/57 cells stimulated with a combina-
tion of anti-T112 + anti-T113 mAbs (1,200 ng/ml/106 cells
vs. 0.1-1.8 ng/ml/106 cells). Similarly, as shown in Table 1
(Exp. 1), the stimulation of MC/64.1 mast cells with anti-
T112 mAb alone induced the production of 11,6 comparable
in magnitude with the amount produced by the combina-
tion of antiT112 + anti T113 (1,500 vs. 2,300 ng/ml/106
cells). Likewise, the antiT113 mAb by itself was capable of
inducing MC/64.1 cells to produce 11,6. Note that the stim-
ulation of MC/64.1 mast cells with either control IgG2a or
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control IgG3 mAbs resulted in little or no IL6 production.
Thus, in the MC/64.1 mast cells, crosslinking ofmore than
one T11 epitope on CD2 is not an absolute requirement for
the generation of signals leading to production of IL6.
In this context, it is known that mast cells express Fcy
receptors including FcyRII (39) to which the above mAbs
could bind. To investigate Fcy receptor ectodomain-inde-
pendent signal transduction via CD2, anti-T112 and anti T113
F(ab)'2 fragments were produced and MC/64.1 cells were
cultured with a combination of anti T112 F(ab)'2 + anti-T113
F(ab)'2 . As shown in Table 2, this stimulation resulted in
production of 11,6 (2,100-3,100 ng/ml/106 cells), compar-
able with that observed with intact antiT112 + antiT113
IgG (Table 1). This result indicates that MC/64 .1 cells can
be activated with a combination of antiT11 mAbs indepen-
dent of Fcy receptor ectodomain binding. Table 2 also shows
that reduced but clearly significant IL6 productionwas trig-
gered by addition of antiT113 F(ab)'2 alone and, to a lesser
extent, by antiT112 F(ab)'2. The amount of IL -6 induced
with either one of the antiT11 F(ab)'2 fragments (Table 2)
was significantly less than the amount of IL6 produced with
any single intact antiT11 mAb (Table 1). Thus, the binding
of intact antiT11 mAbs to FcyRII or FcyRII as well as to
CD2 in MC/64.1 cells apparently enhances induction of1176.
In contrast, a mouse anti-H-2Db mAb, which is of the same
IgG2a isotype as anti-T112, failed to induce any 11,6 produc-
tion in MC/64.1 (Table 1), indicating that the mere binding
of antibody to both H-2Db and Fcy receptor molecules is
not sufficient to trigger IL-6 production.
To more definitively examine the role of the Fcy receptor
in CD2-mediated IL6 production, two types of blocking
studies were performed. In the first experiment, mAb 2.4G2,
which recognizes both FcyRII and FcyRII (34), was added
to the culture along with anti-T112 mAb. As shown in Table
3, 2AG2 addition markedly reduced antiT112-induced 11,6
production and was itself without any activatory effect. In
a separate experiment, isotype-matchedIgG2a control mAb
used in 10-fold excess of antiT112 mAb completely blocked
11,6 induction. Taken together, these findings show that the
Table 2.
￿
Fcy Receptor Ectodomain-independent IL-6 Induction
through Human CD2
The methods are as described in the legend of Table 1. Exp. 1 with anti-
T11 F(ab)'2 fragments was done in parallel with Exp. 2 of Table 1.
IL-6 produced by
MC/64.1
Stimulus Exp. 1 Exp. 2
ng/ml/106 cells
Media 0.4 0.25
T112 F(ab)'2 22 44
T113 F(ab)'2 580 260
T112 F(2b)'2 + T113 F(ab)'2 2,100 3,100Table 3.
￿
Fcy Receptor Ectodomain-dependent IL-6 Induction
through Human CD2
Stimulus
Media
Anti-FcyRII (2.4G2)
Anti-T11 2
Anti-T112+anti-FcyRII (2.4G2)
Anti-T11 2 +control IgG2a (100 P,g/ml)
Anti-T11 2 +control IgG2a (10 Ag/ml)
Control IgG2a (100 Ag/ml)
Control IgG2a (10 ug/ml)
PMA
IL-6 produced
by MC/64.1
<0.5
<0.5
1,100
106 MC/64 .1 cells were incubated with either 5 gg/ml ofmAb 2AG2,
which recognizes FcyRII and FcyRII, or indicated concentrations of
control IgG2a mAb for 45 min at room temperature . They were fur-
ther incubated for 24 h in the presence or absence of 10 pg/ml of anti-
T112 mAb .
CD2-mediated signal transduction pathway in MC/64.1 mast
cells occurs via both Fcy receptor ectodomain-binding inde-
pendent and dependent mechanisms .
CD2 Couples to the HistamineReleasePathway in Mast Cell
Transfectants. Stimulation ofmast cells via the FceRI receptor
isknown to induce histamine release. To determine whether
CD2 stimulation couples to the histamine release pathway,
MC/57.1 and MC/64.1 were stimulated with anti-T112 +
antiT113 mAbs or antiT112 alone for 1 h and supernatants
examined for histamine content byRIA . As shown in Table
4, a combination of anti T112 + anti T113 or antiT112 alone
showed stimulation to the same degree as stimulation by cross-
linking of FceRI by IgE/DNP-BSA in MC/64.1 . Similar
results were obtained when MC/64.1 was examined after 10
min of stimulation (data not shown) . Note that, as expected,
anti-CD2 mAbs had no effect on MC/57.1 . These results
in conjunction with the above studies demonstrate thatCD2
couples to both 11,6 and histamine release pathways in mast
cells .
Mast Cell Line MC/S7 Does not Express CD3~ or CD3rl .
Recent biochemical analysis of human FcyRIII (CD16) on
human NK cells reveals that CD16 is associated with theTCR
CD3~ subunit (22, 23) . In addition, it is thought that the
FceRly, which is homologous toCD3~, associates with CD16
inhumanNK cells (24), and FcyRIII in murine macrophages
and mast cells (26) . We thus examined if murine mast cells
expressing FceRI and FcyRIII also expressCD3~or the related
CD3r1, since one or both might be involved in CD2-mediated
signal transduction in the MC/64.1 mast cell line . To this
end, Northern blot analysis was performed using specific
cDNA probes for CD3~, CD3q, and FcERIy, with RNA
from the MC/57 parental mast cell line, a murine T cell hy-
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Table 4.
￿
CD2-mediated Histamine Release in Mast Cell
Transfectants
Histamine release
Supernatants from 106 mast cells stimulated for 1 h under various con-
ditions were tested for histamine content by RIA as described in Mate-
rials and Methods. Results are representative of two experiments .
bridoma 2114.11 known to express both CD3r and CD3?1
and a 2114.11 variant, termed MA5.8, that lacks CD3~ and
CD3rl (37) . As shown in Fig . 4, MC/57, like MA5.8, lacks
transcripts corresponding to CD3~ and CD3,q . In contrast,
and as expected, 2114.11 contains transcripts of 2.0 and 1.8
kb, which correspond to CD3~andCD3n, respectively (Fig.
4, b and c) . On the other hand, MC/57 mast cells but not
2114.11 orMA5.8 express a transcript of-0.5 kb, which cor-
responds to themRNA of Fcc-kly (Fig. 4 a) . These results
indicate that the MC/57 mast cell line can transmit signals
via the transfected CD2 gene product in the absence ofCD3~
or CD3,q .
Figure4 .
￿
Northernblot analysis ofCD3~, CD3rt, and FeER-y subunit
gene expression in MC/57 mast cells (C57) . 10 Ag of totalRNA isolated
from the indicated cells was size fractionated on a 1% agarose gel con-
taining formaldehyde and transferred to nitrocellulose. Subsequently, the
filter was hybridized with a CD3q-specific probe, washed, and exposed
at -70°C for 1.5 d with an intensifying screen (c) . The filter was then
stripped, reprobed with a CD3I'-specific probe, and exposed for 4 d (b) .
After stripping once more, the filter was hybridized with a probe for the
FcERIy subunit and exposed for 2 .5 d (a) . Positions of ribosomal 28S and
18S RNAs are indicated.
nglml/10 6 cells
<0.5
Stimulus MC/57
nM/106
MC/64.1
cellslml
0.5 Media 8 .7 15.0
440 Anti-T112 + anti-T113 8 .0 95.0
33 Anti-T112 - 75.0
1 Anti-DNP-IgE/DNP-BSA 63 96.0
690Discussion
In an effort to better understand the nature of TCR-
independent CD2 signal transduction, we performed CD2
transduction studies usingmast cells as recipients. The latter
were chosen based on the premise that Fc receptors might
function in lieu of the TCR for transduction coupling to
CD2 in some cells and to determine whether CD2 signal
transduction might be operative in nonlymphoid cells. The
present study provides new insight into both the signal trans-
duction mechanism of CD2 and the pathway ofIL6 produc-
tion and histamine release. Our results indicate that when
human CD2 is expressed in mast cells, perturbation of the
extracellular segment with a combination of antiT112 +
anti-T113 mAb leads to an increase in [Ca2+];, IL6 produc-
tion, and histamine release. IL6 production can be mediated
independently of the extracellular segment of Fcy receptor
since F(ab)'2 fragments of these same mAbs induced IL6
productioncomparable with that obtained with intact mAbs.
In addition, we observed that crosslinking of the CD2 with
Fcy receptor using a single antiT112 or antiT113 mAb could
also stimulate IL6 production. Under these latter circum-
stances, the crosslinking apparently results from the Fe portion
ofthe mAb binding to Fcy receptor and the antigen-binding
sites of the same mAb ligating to CD2, thereby approximating
CD2 and FCy receptor structures.
Cytokine gene activation studies conducted on parental
MC/57 mast cells by Burd et al. (38) with a panel of ac-
tivating agents showed that the 11,6 gene activation can be
induced independently of FceRl. Activation by PMA or Con
A, as well as through FceRI, resulted in the induction of
IL-6 mRNA as detected by Northern blot analysis. Interest-
ingly, the calcium ionophore A23187 did not induce the IL-6
gene in these MC/57 cells, whereas translocation of protein
kinase C by itself was sufficientfor IL6 gene induction, indi-
cating that Ca2+ mobilization is not essential for 11,6 induc-
tion. In contrast to the failure of calcium ionophore to in-
duce the IL6 gene, it has been shown that a calcium ionophore
is itself sufficient to mimic IgE-dependent histamine release
in mast cells (40). These findings indicate that histamine re-
leaseand IL-6 production utilize different signal transduction
mechanisms in mast cells.
Additional evidence for a calcium-independent mechanism
for IL-6 production was obtained from the present study. A
single ant-T112 mAb that failed to induce Ca2+ mobiliza-
tion in MC/64.1 cells was capable of inducing 1176 in these
same cells. On the other hand, the combination of antiT112
+ anti T113 mAbs induces Ca2+ mobilization and IL6.
These results clearly indicate that 11,6 productionis induced
either in the presence or absence of Ca2+ mobilization. Al-
though activation through CD2 produced less Ca2+ mobili-
zation relative to activation via FceRI (Fig. 2 d compared
with 2, a and c), the amount of IL-6 produced upon CD2
stimulation was significantly higher than IL-6 produced after
activation through FceRI (Table 1). The dichotomy observed
between Ca 2+ mobilization and IL-6 induction through
CD2 and FceRI may be explicable if several transduction
pathways operate in parallel in the mast cell. It is likely that
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a Cat+-independent pathway plays a significant role in the
induction of IL6 after activation via either CD2 or FceRI.
This pathway may include a Cat+-independent activation of
protein tyrosine kinase (PTK), which has already been demon-
strated in rat basophilic leukemia cells upon triggering through
FceRI (41) . It is thus possible that the MC/64.1, mast cells
may utilize a PTK pathway for IL6 induction. Interestingly,
it was shown that tyrosine phosphorylation (in the absence
of extracellular calcium) is not sufficient to induce histamine
release and required the presence of calcium in the extracel-
lularmedia. This finding is consistent with the fact that cal-
cium mobilization in mast cells can lead to histamine release
(40). However, the ability of anti-T112 mAb to trigger hista-
mine release (Table 4) without a detectable increase in [Ca 2+];
(Fig. 2) implies an additional complexity to the process of
histamine release.
Our observations that an activatory combination of anti-
T112 + anti-T113 mAbs causes calcium mobilization, pro-
duction of IL6, and histamine release on human CD2-
transfected MC/64.1 mast cells in the absence of TCR
expression (Fig. 2 d and Table 1) is somewhat analogous to
the situation in CD3 - thymocytes. Previous studies with
thymocytes have shown that the same combination of anti-
T112 + anti-T113 mAbs causes a mobilization of [Ca2+]i and
I1r2R expression (9, 9a). Although the activation require-
ments for IL2R expression and IL6 induction are not directly
comparable, TCRindependent human CD2 signal trans-
duction in MC/64.1 cells and thymocytes results in both an
early change in the ionic milieu of the cell and activation
of gene programs. Moreover, the observation that a single
anti-T112 antibody is incapable ofmobilizing [Ca211, in these
MC/64.1 mast cells (Fig. 2, e) is consistent with the activa-
tory requirements of TCRindependent signaling in CD3 -
thymocytes (9).
The TCR-independent human CD2 signal transduction
obtained with MC/64.1 cells is also reminiscent of the acti-
vation requirements in CD2+CD3 - NK cells. Anti-T112 +
anti T113 mAbs activate NK cells to lyse their target (4).
Moreover, F(ab)'2 fragments of anti-T112 + anti-T113 mAbs,
which activate MC/64.1 cellsto produce IL6 (Table 2), have
also been shown to activate NK cells to lyse target (42). Thus,
an Fcy receptor ectodomain-independent mechanism ofhuman
CD2 signal transduction is operative in both MC/64.1 cells
and NK cells. On the other hand, it should be noted that
human NK cells express FcyRIII (CD16), and single anti-
CD2 mAbs activate NK cells in the same way that a single
anti-CD2 mAb can induce IL -6 productionin MC/64.1 cells.
For example, in one report, a single anti-CD2 mAb CLB-
T11 was shown to induce cytolysic activity of CD3 - CD16+
NK cells (5). In a second independent study, Annasetti et
al. (43) showed that the addition of an anti-CD2 mAb 9.1
but not its F(ab)'2 fragment to CD3 - CD16+ NK cell lines
resulted in cytolysis oftargets. The observation of Fcy receptor
ectodomain dependency in NK cell activation is consistent
with our observation in mast cells that F(ab)'2 fragments of
either antiT112 or antiT113 mAbs were not as efficient as
a single intact antiT112 or antiT113 mAb in inducing IL-6production in MC/64.1 cells (Tables 1 and 2). Perhaps more
importantly, a mAb that recognizes both FcyRII and FcyRIII
or excess control IgG2a isotype-matched mAb blocks anti-
CD2-mediated activation ofIIr6 productionby a single anti-
CD2 mAb in CD2-transfected mast cells. Hence, it is likely
that the ectodomain of FcyRIII, the murine homologue of
human CD16 (44, 45), is involved in CD2 signal transduc-
tion when a single anti-CD2 mAb binds to CD2 in both
mouse MC/64.1 and human NK cells. Crosslinking of
H-2Db molecules to Fcy receptor failed to stimulate any
significant amount of IIr6 (Table 1). Therefore, crosslinking
of Fcy receptors to other unrelated molecules is not neces-
sarily capable ofinducing activation. These results collectively
indicate that activation pathways involving Fcy receptor
ectodomain-dependent and -independent mechanisms operate
in TCR-independent activation through CD2.
Other studies have shown that Fc receptors on both mast
cellsand NK cells function as signal transduction molecules.
Crosslinking of CD16 molecules (FcyRIII) by certain anti-
CD16 mAbs activate human NK cells (46). Similarly, cross-
linking of the FceRI on both the parental MC/57 and human
CD2 transfected MC/64.1 cells with a combination of IgE
anti-DNP mAb and DNP-BSA resulted in mobilization of
[Ca2+]i and IIr6 production (Fig. 2, a and c, and Table 1)
(38). With respect to the structure of the FceRI and FcyRIII
expressed on mast cells, it is known that they both share a
common y subunit, FceRIy (26). FceRIy has been shown
to have substantial homology with CD3 subunits ofthe TCR
including CD3 ' and CD37I subunits (36, 47, 48) . Recent
studies on human NK cells have revealed that the CD3'
subunit is associated with CD16 in the absence of the other
TCR subunits (22, 23, 49). In addition, studies conducted
on the expression of CD16 suggested that FceRIy is associated
with CD16 (24). Given the fact that there is evidence sug-
gesting that the C132-mediated activation of NK cells re-
quires the coexpression ofCD16 (46), it is possible that CD2
functionally couples to either the CD3' or FceRIy subunit
or both. Our findings by Northern analysis that the CD2-
transfected MC/64.1 mast cells do not express any CD3' or
related CD3r7 indicate that these subunits are not essential
for CD2 signalling (Fig. 4) . In view of the aforementioned
expression data, it is tempting to speculate that the FceRIy
subunit is a structure involved in the functional coupling of
CD2 and FcyRIII on MC/64.1 cells.
In addition to NK cells and thymocytes, murine B cells
express CD2 in the absence ofTCR (50). Although it is not
known whether murine CD2 transmits activation signals,
the fact that both murine and human CD2 are highly ho-
mologous and share a long cytoplasmic tail suggests that mu-
rine CD2 has a similar role in B cell activation (50, 51). In
this respect, CD2 on murine B cells may also couple with
signal transduction elements on Fcy receptors or membrane
immunoglobulins. The recent demonstration that the B cell
antigen receptor of the IgM class is noncovalently associated
with another subunit termed mb-1 (52), which has a cyto-
plasmic tail consisting ofa motifshared between CD3 subunits
and FceRIy (48, 53) (as described below), suggests that mb-1
may couple functionally to murine CD2 on B cells.
The FceRIy subunit of FceRI also appears to be a compo-
nent of murine FcyRIII (26) and human FcyRIII (CD16)
(24), and bears significant homology to CD3'/q (36, 47,
48). The localization of FceRIy and CD3"/r7 subunit genes
to mouse chromosome 1(27, 28), their similar genomic and
structural organization, and the sequence homologies between
exon 2 encoding the transmembrane region of both genes
and between the last two exons of the cytoplasmic domains
suggest that they belong to a new family of genes that play
a significant role in signal transduction (36, 47). The func-
tional relevance of the primary sequence homology between
CD3' and the FceRIy subunit has been provided by a recent
experiment in Xenopus oocytes showing that CD3" can sub-
stitute for FceRIy in the assembly and surface expression of
FceRI (54). Moreover, a conserved amino acid motif (D [or
EjxxYxxLxxxxxxxYxxL[orI]) is present
in the cytoplasmic domains of receptor molecules such as
FceRIy, CD3', CD3,q, and mb-1 (48). Amino acid residues
composing the motif(upper case letters and underlined: mouse
FceRIy [DavYtgLntrsgetYetL; as 62-79], mouse CD3'
[Dg1YagL_statkdtYdaL; as 118-135], mouse CD3'/CD3q [Eg-
vYnaL_gkdkmaeaYseI; as 87-105], mouse mb-1 [EneYegLnl-
ddcsmyedI; as 179-196]) would be expected to lie on the
same side of an a-helical barrel if the cytoplasmic sequence
formed an a helix. As such, the residues could form a binding
site for putative proteins involved in the generation ofsignals
after receptor crosslinking. Therefore, it is possible that the
FceRIy subunit shared between murine FceRI and FcyRIII
is involved in coupling with the CD2-mediated signal trans-
duction pathway in MC/64.1 cells. It seems likely that the
TCRindependent CD2 signalling machinery is linked to the
FceRIy, CD3', and/or CD371 and mb-1 subunits in some
cells such as CD3- NK cells, thymocytes, and murine B
cells. Further analysis, including reconstitution of CD2-
mediated signal transduction in TCR - Jurkat variants by
transfection with CD16 or other Fc receptors, could provide
additional evidence for this hypothesis.
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